Navigation Links
Micromet Closes $80.5 Million Public Offering of Common Stock
Date:8/4/2009

oclonal antibodies. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's immune system to eliminate cancer cells. Five of Micromet's antibodies are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform techno
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
2. Micromet Announces Pricing of Public Offering of Common Stock
3. Micromet Announces Public Offering of Common Stock
4. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
5. Micromet Added to Russell 3000 Index
6. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
7. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
8. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
9. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
10. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
11. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
(Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... the enterprise replication cluster, faster loading speeds, higher ... Elasticsearch. This release happens to coincide with a ... GraphDB™ was formerly known as OWLIM. ... enterprise resilient RDF triplestore will also benefit from ...
(Date:8/19/2014)... Research and Markets  has announced the addition of ... Report" report to their offering. This report ... US$ Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
... the first time observed chemical reactions near absolute zero, ... that reaction rates can be controlled using quantum mechanics, ... results and techniques, described in the Feb. 12 issue ... unknown aspects of how molecules interact, a key to ...
... , CINCINNATI , ... it will release its fourth quarter and full-year 2009 financial results after ... will host a telephone conference call and simultaneous webcast on Thursday, ... and answer session will follow. , Conference Call Instructions ...
... , , , ... /PRNewswire-Asia/ -- The January issue of,"Neuropharmacology", publishes the article ... (MLC 601) protective effects on neuronal and brain,injuries as well ... The French research team was led by Prof. ...
Cached Biology Technology:Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 2Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 3Seeing the quantum in chemistry: JILA scientists control chemical reactions of ultracold molecules 4Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast 2Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast 3Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD 2Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD 3
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
(Date:8/21/2014)... LAWRENCE A study recently published in the journal ... Kansas shows a new role for the protein adenomatous ... second-leading cause of cancer-related deaths in the U.S. , ... of Molecular Biosciences and co-leader of the Cancer Biology ... better part of her career trying to understand the ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... the world began to warm, a swath of the North ... biological productivity 14,000 years ago, this stretch of the sea ... thrived in large numbers until the productivity endedas mysteriously as ... have hypothesized that iron sparked this surge of ocean life, ...
... Selective grazing by slugs may prevent key grassland species ... hay meadows, new research has shown., Work by scientists ... slugs have on grassland biodiversity and how this might ... to chew through a gardener,s prize petunias or strawberry ...
... tissue function and regeneration is supported by stem cells, ... Yixian Zheng and Haiyang Chen identifies an important component ... building and function. The results could have implications for ... Cell . Lamins are proteins that the major ...
Cached Biology News:Scientists solve a 14,000-year-old ocean mystery 2Scientists solve a 14,000-year-old ocean mystery 3Grazing slugs hinder grassland restoration 2Stem cell clues uncovered 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
... Mucin 3 (MUC3) is a glycoprotein. ... to a lesser extent in breast, lung ... Ab-2 shows no cross-reaction with MUC1 and ... the human MUC3 Immunogen: MUC3 ...
... CDX2, a member of the caudal-related homeobox ... regulates both proliferation and differentiation in intestinal ... in triggering cells towards the phenotype of ... the maintenance of the phenotype. Clone CDX2-88 ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Biology Products: